Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155 140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study
Objective: To determine the association of distinct clinical subsets with myositis-specific autoantibodies (MSAs) towards anti-155 140-kDa polypeptides [anti-155 140 antibodies (Abs)], anti-140-kDa polypeptides (anti-140 Abs), and anti-aminoacyl tRNA synthetases (ARS Abs) in Japanese patients with d...
Saved in:
Published in | Scandinavian journal of rheumatology Vol. 38; no. 4; pp. 263 - 267 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Colchester
Informa UK Ltd
2009
Taylor & Francis Informa |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective: To determine the association of distinct clinical subsets with myositis-specific autoantibodies (MSAs) towards anti-155 140-kDa polypeptides [anti-155 140 antibodies (Abs)], anti-140-kDa polypeptides (anti-140 Abs), and anti-aminoacyl tRNA synthetases (ARS Abs) in Japanese patients with dermatomyositis (DM).
Methods: We compared the clinical features and short-term prognoses of 30 DM patients whose serological status included these MSAs. The MSAs were determined by immunoprecipitation.
Results: Anti-155 140 Abs (n = 5), anti-140 Abs (n = 8), and anti-ARS Abs (n = 7) did not overlap each other. All of the anti-155 140 Ab-positive patients (n = 5) were complicated by malignancies, as were all of the anti-140 Ab-positive patients (n = 8), who showed rapidly progressive interstitial lung disease (ILD). The survival rate at 6 months from the diagnosis of DM was significantly lower in the anti-140 Ab-positive patients than in the other patients.
Conclusion: This is the first study to report, in a single cohort of DM patients, that distinct clinical subsets are distributed in an anti-155 140 Ab-positive group, an anti-140 Ab-positive group, or an anti-ARS Ab-positive group. Our data also confirm previous evidence that anti-155 140 Abs are involved in malignancies and that anti-140 Abs are involved in rapidly progressive ILD. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0300-9742 1502-7732 |
DOI: | 10.1080/03009740802687455 |